Pfizer Inc. is taking over Biohaven Pharmaceutical Holding Co. Ltd. for $11.6 billion to bring aboard Nurtec ODT (rimegepant), the calcitonin gene-related peptide (CGRP) receptor antagonist first approved in February 2020 for acute migraine in adults with or without aura. Read More
With a 2020 launch behind it, Moma Therapeutics Inc. has completed a $150 series B financing to continue refining its pipeline of therapies targeting tough-to-drug enzymes in treating solid tumors. Read More
News of government prosecutors actively going after individuals for defrauding the U.S. health care system has become commonplace, but the government’s focus on criminally prosecuting fraud against Medicare, Medicaid and other government programs could make biopharma companies’ patient assistance programs a more attractive target. Read More
First results from the U.K. Cov-Boost trial, looking at responses to a fourth dose of an mRNA COVID-19 vaccine, show that antibody levels increase more than after the third dose, confirming the precautionary move to give the most vulnerable a second COVID-19 booster in advance of immune response data being available. Read More
Not long ago, people who touted the prospects of psychedelic drugs might have been accused of hallucinating, but in the U.S. and elsewhere the space has expanded in recent years, as mental health treatments remain “stuck where cancer was 50 years ago,” said Roth analyst Elemer Piros. Read More
A congressional investigation into COVID-19 vaccine manufacturing failures at Emergent Biosolutions Inc. unveiled more troubling issues at the company’s Bayview facility in Baltimore, which had been awarded a lucrative U.S. government contract to produce vaccines for Johnson & Johnson. Read More
New hires and promotions in the biopharma industry, including: Augustine, Boston, Immpact, Longeveron, Lutris, Medincell, Neximmune, NMD, Onconano, Oncorus, Pneumagen. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: AC Immune, Adocia, Athira, Bio-Thera, Eledon, Imago, Lianbio, Mereo, Moonlake, NIH, Nykode, Oxurion. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aum, Blade, Bristol, Celsion, Comera, Cortexyme, Dyadic, Evotec, FSD, Ibio, Merck, Modex, Novosteo, Opko, Pfizer, Roche, Venus. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Acer, Elpiscience, Logicbio, Resverlogix, Selection, Teva, Therapeutics Solutions. Read More
